Your browser doesn't support javascript.
loading
P53 mutations in Ewing's sarcoma.
Park, Y K; Chi, S G; Kim, Y W; Park, H R; Unni, K K.
Afiliação
  • Park YK; Department of Pathology, Kyung Hee University Hospital, Dongdaemoon-gu, Seoul 130-702, Korea. ykpark@khmc.or.kr
Oncol Rep ; 8(3): 533-7, 2001.
Article em En | MEDLINE | ID: mdl-11295075
The p53 tumor suppressor gene is one of the most frequently altered genes in human malignancies. To explore the implication of p53 alteration in Ewing's sarcoma, we analyzed the deletion and sequence alterations of p53 and abnormal amplification of MDM2, which acts as a functional inhibitor of p53, in 35 tissue specimens. Quantitative genomic PCR analysis showed that 2 of 35 tumors have extremely low levels of the p53 gene, indicating a homozygous deletion of the gene. Mutational analysis of exons 4 to 9 of p53 by PCR-SSCP revealed that 3 of 35 tumors carry sequence alterations in exons 5 or 8, and DNA sequencing analysis identified missense point mutations at codon 132 (AAG-->ATG, lysine-->methionine) and codon 135 (TGC-->TCC, cystein-->serine) in exon 5, and codon 287 (GAG-->GTG, glutamic acid-->valine) in exon 8 from these tumors. No abnormal amplification of the MDM2 gene was recognized. Taken together, our data demonstrate that p53 is genetically altered in a small fraction of Ewing's sarcoma.
Assuntos
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sarcoma de Ewing / Neoplasias Ósseas / Proteínas Nucleares / Genes p53 / Mutação Puntual Limite: Humans / Male Idioma: En Ano de publicação: 2001 Tipo de documento: Article
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sarcoma de Ewing / Neoplasias Ósseas / Proteínas Nucleares / Genes p53 / Mutação Puntual Limite: Humans / Male Idioma: En Ano de publicação: 2001 Tipo de documento: Article